<table id="table2" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2 Rifabutin Interaction Studies</caption>
<col align="left" valign="top" width="15%"></col>
<col align="left" valign="top" width="14%"></col>
<col align="left" valign="top" width="12%"></col>
<col align="left" valign="top" width="13%"></col>
<col align="left" valign="top" width="13%"></col>
<col align="left" valign="top" width="13%"></col>
<col align="left" valign="top" width="20%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule">Coadministered drug</th>
<th stylecode="Rrule">Dosing regimen of coadministered drug</th>
<th stylecode="Rrule">Dosing regimen of rifabutin</th>
<th stylecode="Rrule">Study population (n)</th>
<th stylecode="Rrule">Effect on rifabutin</th>
<th align="center" stylecode="Rrule">Effect on coadministered drug</th>
<th stylecode="Rrule">Recommendation</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="7">↑ indicates increase; ↓ indicates decrease; ↔ indicates no significant change
              
    
     <br/>QD- once daily; BID- twice daily; TID – thrice daily
              
    
     <br/>ND - No Data
              
    
     <br/>AUC - Area under the Concentration vs. Time Curve; C
              
    
     <sub>max</sub> - Maximum serum concentration
             
   
    </td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td align="left" colspan="7" stylecode="Lrule Rrule">
<content stylecode="bold">ANTIVIRALS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Amprenavir</td>
<td stylecode="Rrule">1200 mg BID × 10 days</td>
<td stylecode="Rrule">300 mg QD × 10 days</td>
<td stylecode="Rrule">Healthy male subjects (6)</td>
<td stylecode="Rrule">↑ AUC by 193%,
              
    
     <br/>↑ Cmax by 119%
             
   
    </td>
<td align="center" stylecode="Rrule">↔</td>
<td stylecode="Rrule">Reduce rifabutin dose by at least 50%. Monitor closely for adverse reactions.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Delavirdine</td>
<td stylecode="Rrule">400 mg TID</td>
<td stylecode="Rrule">300 mg QD</td>
<td stylecode="Rrule">HIV-infected patients (7)</td>
<td stylecode="Rrule">↑ AUC by 230%,
              
    
     <br/>↑ Cmax by 128%
             
   
    </td>
<td stylecode="Rrule">↓ AUC by 80%,
              
    
     <br/>↓ Cmax by 75%,
              
    
     <br/>↓ Cmin by 17%
             
   
    </td>
<td stylecode="Rrule">
<content stylecode="bold">CONTRAINDICATED</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Didanosine</td>
<td stylecode="Rrule">167 or 250 mg BID × 12 days</td>
<td stylecode="Rrule">300 or 600 mg QD × 1</td>
<td stylecode="Rrule">HIV-infected patients (11)</td>
<td align="center" stylecode="Rrule">↔</td>
<td align="center" stylecode="Rrule">↔</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Fosamprenavir/ ritonavir</td>
<td stylecode="Rrule">700 mg BID plus ritonavir 100 mg BID × 2 weeks</td>
<td stylecode="Rrule">150 mg every other day × 2 weeks</td>
<td stylecode="Rrule">Healthy subjects (15)</td>
<td stylecode="Rrule">↔ AUC
              
    
     <footnote id="K1583">compared to rifabutin 300 mg QD alone</footnote>
<br/>↓ Cmax by 15%
             
   
    </td>
<td stylecode="Rrule">↑ AUC by 35%
              
    
     <footnote id="K1590">compared to historical control (fosamprenavir/ritonavir 700/100 mg BID)</footnote>,
              
    
     <br/>↑ Cmax by 36%,
              
    
     <br/>↑ Cmin by 36%,
             
   
    </td>
<td stylecode="Rrule">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with fosamprenavir/ritonavir combination.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Indinavir</td>
<td stylecode="Rrule">800 mg TID × 10 days</td>
<td stylecode="Rrule">300 mg QD × 10 days</td>
<td stylecode="Rrule">Healthy subjects (10)</td>
<td stylecode="Rrule">↑ AUC by 173%,
              
    
     <br/>↑ Cmax by 134%
             
   
    </td>
<td stylecode="Rrule">↓ AUC by 34%,
              
    
     <br/>↓ Cmax by 25%,
              
    
     <br/>↓ Cmin by 39%
             
   
    </td>
<td stylecode="Rrule">Reduce rifabutin dose by 50%, and increase indinavir dose from 800 mg to 1000 mg TID.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Lopinavir/ ritonavir</td>
<td stylecode="Rrule">400/100 mg BID × 20 days</td>
<td stylecode="Rrule">150 mg QD × 10 days</td>
<td stylecode="Rrule">Healthy subjects (14)</td>
<td stylecode="Rrule">↑ AUC by 203% 
              
    
     <footnote id="K1646">also taking zidovudine 500 mg QD</footnote>
<br/>↓ Cmax by 112%
             
   
    </td>
<td align="center" stylecode="Rrule">↔</td>
<td stylecode="Rrule">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with lopinavir/ritonavir combination. Monitor closely for adverse reactions.  Reduce rifabutin dosage further, as needed.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Saquinavir/ ritonavir</td>
<td stylecode="Rrule">1000/100 mg BID × 14 or 22 days</td>
<td stylecode="Rrule">150 mg every 3 days × 21–22 days</td>
<td stylecode="Rrule">Healthy subjects</td>
<td stylecode="Rrule">↑ AUC by 53% 
              
    
     <footnote id="K1674">compared to rifabutin 150 mg QD alone</footnote>
<br/>↑ Cmax by 88%
              
    
     <br/>(n=11)
             
   
    </td>
<td stylecode="Rrule">↓ AUC by 13%,
              
    
     <br/>↓ Cmax by 15%,
              
    
     <br/>(n=19)
             
   
    </td>
<td stylecode="Rrule">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with saquinavir/ritonavir combination. Monitor closely for adverse reactions.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ritonavir</td>
<td stylecode="Rrule">500mg BID × 10 days</td>
<td stylecode="Rrule">150 mg QD × 16 days</td>
<td stylecode="Rrule">Healthy subjects (5)</td>
<td stylecode="Rrule">↑ AUC by 300%,
              
    
     <br/>↑ Cmax by 150%
             
   
    </td>
<td align="center" stylecode="Rrule">ND</td>
<td stylecode="Rrule">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with lopinavir/ritonavir combination. Monitor closely for adverse reactions.
              
    
     <br/>Reduce rifabutin dosage further, as needed.
             
   
    </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Tipranavir/ ritonavir</td>
<td stylecode="Rrule">500/200 BID × 15 doses</td>
<td stylecode="Rrule">150 mg single dose</td>
<td stylecode="Rrule">Healthy subjects (20)</td>
<td stylecode="Rrule">↑ AUC by 190%,
              
    
     <br/>↑ Cmax by 70%
             
   
    </td>
<td align="center" stylecode="Rrule">↔</td>
<td stylecode="Rrule">Reduce rifabutin dose by at least 75% (to a maximum 150 mg every other day or three times per week) when given with tipranavir/ritonavir combination. Monitor closely for adverse reactions. Reduce rifabutin dosage further, as needed.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Nelfinavir</td>
<td stylecode="Rrule">1250 mg BID × 7–8 days</td>
<td stylecode="Rrule">150 mg QD × 8 days</td>
<td stylecode="Rrule">HIV-infected patients (11)</td>
<td stylecode="Rrule">↑ AUC by 83%, 
              
    
     <footnote id="K1761">compared to rifabutin 300 mg QD alone</footnote>
<br/>↑ Cmax by 19%
             
   
    </td>
<td align="center" stylecode="Rrule">↔</td>
<td stylecode="Rrule">Reduce rifabutin dose by 50% (to 150 mg QD) and increase the nelfinavir dose to 1250 mg BID</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Zidovudine</td>
<td stylecode="Rrule">100 or 200 mg q4h</td>
<td stylecode="Rrule">300 or 450 mg QD</td>
<td stylecode="Rrule">HIV-infected patients (16)</td>
<td align="center" stylecode="Rrule">↔</td>
<td stylecode="Rrule">↓ AUC by 32%,
              
    
     <br/>↓ Cmax by 48%,
             
   
    </td>
<td stylecode="Rrule">Because zidovudine levels remained within the therapeutic range during coadministration of rifabutin, dosage  adjustments are not necessary.</td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="7" stylecode="Lrule Rrule">
<content stylecode="bold">ANTIFUNGALS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Fluconazole</td>
<td stylecode="Rrule">200 mg QD × 2 weeks</td>
<td stylecode="Rrule">300 mg QD × 2 weeks</td>
<td stylecode="Rrule">HIV-infected patients (12)</td>
<td stylecode="Rrule">↑ AUC by 82%,
              
    
     <br/>↑ Cmax by 88%
             
   
    </td>
<td align="center" stylecode="Rrule">↔</td>
<td stylecode="Rrule">Monitor for rifabutin associated adverse events. Reduce rifabutin dose or suspend MYCOBUTIN use if toxicity is suspected.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Posaconazole</td>
<td stylecode="Rrule">200 mg QD × 10 days</td>
<td stylecode="Rrule">300 mg QD × 17 days</td>
<td stylecode="Rrule">Healthy subjects (8)</td>
<td stylecode="Rrule">↑ AUC by 72%,
              
    
     <br/>↑ Cmax by 31%
             
   
    </td>
<td stylecode="Rrule">↓ AUC by 49%,
              
    
     <br/>↓ Cmax by 43%
             
   
    </td>
<td stylecode="Rrule">If co-administration of these two drugs cannot be avoided, patients should be monitored for adverse events associated with rifabutin administration, and lack of posaconazole efficacy.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Itraconazole</td>
<td stylecode="Rrule">200 mg QD</td>
<td stylecode="Rrule">300 mg QD</td>
<td stylecode="Rrule">HIV-Infected patients (6)</td>
<td align="center" stylecode="Rrule">↑
              
    
     <footnote id="K1878">data from a case report</footnote>
</td>
<td stylecode="Rrule">↓ AUC by 70%,
              
    
     <br/>↓ Cmax by 75%,
             
   
    </td>
<td stylecode="Rrule">If co-administration of these two drugs cannot be avoided, patients should be monitored for adverse events associated with rifabutin administration, and lack of itraconazole efficacy. In a separate study, one case of uveitis was associated with increased serum rifabutin levels following co-administration of rifabutin (300 mg QD) with itraconazole (600–900 mg QD).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Voriconazole</td>
<td stylecode="Rrule">400 mg BID × 7 days (maintenance dose)</td>
<td stylecode="Rrule">300 mg QD × 7 days</td>
<td stylecode="Rrule">Healthy male subjects (12)</td>
<td stylecode="Rrule">↑ AUC by 331%,
              
    
     <br/>↑ Cmax by 195%
             
   
    </td>
<td stylecode="Rrule">↑ AUC by ~100%,
              
    
     <br/>↑ Cmax by ~100%
              
    
     <footnote id="K1912">compared to voriconazole 200 mg BID alone</footnote>
</td>
<td stylecode="Rrule">
<content stylecode="bold">CONTRAINDICATED</content>
</td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="7" stylecode="Lrule Rrule">
<content stylecode="bold">ANTI-PCP (Pneumocystis carinii pneumonia)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Dapsone</td>
<td stylecode="Rrule">50 mg QD</td>
<td stylecode="Rrule">300 mg QD</td>
<td stylecode="Rrule">HIV-infected patients (16)</td>
<td stylecode="Rrule">ND</td>
<td align="center" stylecode="Rrule">↓ AUC by 27 –40%</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Sulfamethoxazole- Trimethoprim</td>
<td stylecode="Rrule">800/160 mg</td>
<td stylecode="Rrule">300 mg QD</td>
<td stylecode="Rrule">HIV-infected patients (12)</td>
<td stylecode="Rrule">↔</td>
<td align="center" stylecode="Rrule">↓ AUC by 15–20%</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="7" stylecode="Lrule Rrule">
<content stylecode="bold">ANTI-MAC (Mycobacterium avium intracellulare complex)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Azithromycin</td>
<td stylecode="Rrule">500 mg QD × 1 day, then 250 mg QD × 9 days</td>
<td stylecode="Rrule">300 mg QD</td>
<td stylecode="Rrule">Healthy subjects (6)</td>
<td stylecode="Rrule">↔</td>
<td align="center" stylecode="Rrule">↔</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Clarithromycin</td>
<td stylecode="Rrule">500 mg BID</td>
<td stylecode="Rrule">300 mg QD</td>
<td stylecode="Rrule">HIV-infected patients (12)</td>
<td stylecode="Rrule">↑ AUC by 75%</td>
<td align="center" stylecode="Rrule">↓ AUC by 50%</td>
<td stylecode="Rrule">Monitor for rifabutin associated adverse events. Reduce dose or suspend use of MYCOBUTIN if toxicity is suspected. Alternative treatment for clarithromycin should be considered when treating patients receiving rifabutin</td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="7" stylecode="Lrule Rrule">
<content stylecode="bold">ANTI-TB (Tuberculosis)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ethambutol</td>
<td stylecode="Rrule">1200 mg</td>
<td stylecode="Rrule">300 mg QD × 7 days</td>
<td stylecode="Rrule">Healthy subjects (10)</td>
<td stylecode="Rrule">ND</td>
<td align="center" stylecode="Rrule">↔</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Isoniazid</td>
<td stylecode="Rrule">300 mg</td>
<td stylecode="Rrule">300 mg QD × 7 days</td>
<td stylecode="Rrule">Healthy subjects (6)</td>
<td stylecode="Rrule">ND</td>
<td align="center" stylecode="Rrule">↔</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td align="left" colspan="7" stylecode="Lrule Rrule">
<content stylecode="bold">OTHER</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Methadone</td>
<td stylecode="Rrule">20 – 100 mg QD</td>
<td stylecode="Rrule">300 mg QD × 13 days</td>
<td stylecode="Rrule">HIV-infected patients (24)</td>
<td stylecode="Rrule">ND</td>
<td align="center" stylecode="Rrule">↔</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ethinylestradiol (EE)/Norethindrone (NE)</td>
<td stylecode="Rrule">35 mg EE / 1 mg NE × 21 days</td>
<td stylecode="Rrule">300 mg QD × 10 days</td>
<td stylecode="Rrule">Healthy female subjects (22)</td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">EE: ↓ AUC by
              
    
     <br/>35%, ↓ C
              
    
     <sub>max</sub> by 20%
              
    
     <br/>NE: ↓ AUC by 46%
             
   
    </td>
<td stylecode="Rrule">Patients should be advised to use additional or alternative methods of contraception.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Theophylline</td>
<td stylecode="Rrule">5 mg/kg</td>
<td stylecode="Rrule">300 mg × 14 days</td>
<td stylecode="Rrule">Healthy subjects (11)</td>
<td stylecode="Rrule">ND</td>
<td align="center" stylecode="Rrule">↔</td>
<td stylecode="Rrule"></td>
</tr>
</tbody>
</table>